文献速递乳腺癌

帕妥珠单抗再治疗用于人表皮生长因子受体2阳性局部晚期/转移性乳腺癌(PRECIOUS研究):最终总生存分析

Pertuzumab Retreatment for Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced/Metastatic Breast Cancer (PRECIOUS Study): Final Overall Survival Analysis.
PubMed 文献 · J Clin Oncol · 2025-01-24

PRECIOUS研究最终总生存分析显示,既往接受过含帕妥珠单抗方案治疗的HER2阳性局部晚期/转移性乳腺癌患者中,帕妥珠单抗再治疗联合曲妥珠单抗及医生选择化疗(PTC组)的中位总生存期为36.2个月,优于曲妥珠单抗联合医生选择化疗(TC组)的26.5个月(HR 0.73,单侧95%CI上限0.97)。

要点

  • PTC组中位OS为36.2个月,TC组为26.5个月,HR 0.73(单侧95%CI上限0.97)。
  • 研究者评估的中位PFS:PTC组5.5个月 vs TC组4.2个月,HR 0.81(单侧95%CI上限1.02)。
  • 独立评审的中位PFS两组均为4.4个月,HR 1.03(单侧95%CI上限1.36),未见差异。

核心结论

  • 双HER2阻断(帕妥珠单抗联合曲妥珠单抗)可能有助于改善既往接受过含帕妥珠单抗方案治疗的HER2阳性局部晚期/转移性乳腺癌患者的总生存。

研究设计与样本

  • 开放标签III期PRECIOUS研究,将既往接受过含帕妥珠单抗方案作为局部晚期/转移性乳腺癌一线/二线治疗的患者按1:1随机分配至PTC组(n=110)或TC组(n=109)。

主要发现

  • 中位随访25.8个月,PTC组中位OS为36.2个月,TC组为26.5个月,HR 0.73(单侧95%CI上限0.97)。
  • 更新后研究者评估的中位PFS:PTC组5.5个月 vs TC组4.2个月,HR 0.81(单侧95%CI上限1.02)。
  • 独立评审的中位PFS:PTC组4.4个月 vs TC组4.4个月,HR 1.03(单侧95%CI上限1.36)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In the primary analysis of the open-label phase III PRECIOUS study, pertuzumab retreatment combined with trastuzumab plus chemotherapy of physician's choice (PTC) significantly improved investigator-assessed progression-free survival (PFS) compared with trastuzumab plus physician's choice chemotherapy (TC) in patients with human epidermal growth factor receptor 2 (HER2)-positive locally advanced/metastatic breast cancer (LA/mBC). Here, we report final overall survival (OS) at the median follow-up of 25.8 months. Patients who have previously received pertuzumab-containing regimens as first-/second-line treatment for LA/mBC were randomly assigned 1:1 to two groups, PTC group (n = 110) and TC group (n = 109). Median OS was longer in the PTC group (median OS 36.2 v 26.5 months; hazard ratio [HR], 0.73 [one side 95% CI upper limit, 0.97]). Updated median investigator-assessed PFS (5.5 v 4.2 months; HR, 0.81 [one side 95% CI upper limit, 1.02]) were also better in the PTC group. Median PFS by independent review did not show the difference between the two groups (4.4 v 4.4 months; HR, 1.03 [one side 95% CI upper limit, 1.36]). These findings suggest that dual HER2 blockade with pertuzumab plus trastuzumab could contribute to improving OS in patients who have previously been treated with pertuzumab-containing regimens for HER2-positive LA/mBC.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Yamamoto Y, Iwata H, Saji S, et al. Pertuzumab Retreatment for Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced/Metastatic Breast Cancer (PRECIOUS Study): Final Overall Survival Analysis. J Clin Oncol. 2025. PMID: 39854662. doi:10.1200/JCO-24-01673

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。